论文部分内容阅读
背景与目的:实验和临床证明恶性肿瘤的生长、浸润和转移与肿瘤血管生成有关,这过程由多种血管生长因子调控,如血管内皮生长因子(vascularendothelialgrowthfactor,VEGF)。目前在妇科恶性肿瘤患者中测定血清VEGF水平的研究报道不多。本研究测定妇科恶性肿瘤患者血清中VEGF的水平,并探讨其能否成为一种新的肿瘤标记物。材料与方法:采用R&DSystemsIncminneapolisMNUSA生产的QuantikineHumamVEGF试剂盒,用ELISA方法测定50例宫颈癌、39例子宫内膜癌和89例卵巢癌患者的术前血清,以及其中3例卵巢癌术后3、6、9个月及复发时血清的VEGF水平;另用80例健康妇女血清的VEGF水平作为对照。用SPSS9.0统计软件包进行统计分析。用5th和95th位数的区间描述变异程度。结果:80例健康妇女的血清VEGF中位水平为218.5ng/L(42.06-671.70ng/L)。50例宫颈癌、39例子宫内膜癌和89例卵巢癌患者术前血VEGF中位水平分别为272.00ng/L(91.94-745.53ng/L)、383.50ng/L(105.67-776.50ng/L)和479.85ng/L(99.47-1326.88ng/L),子宫内膜癌和卵巢癌患者术前血清VEGF水平显著高于健康妇女(P<0.0001),宫颈癌患者术前血清VEGF与健康妇女相比无显著性差异(P>0.05)。3例卵巢癌患者术后3、6、9个月无复发时测定的血清VEGF水平较术前明显下降,其中2例术
BACKGROUND & AIM: Experimental and clinical evidences suggest that the growth, invasion and metastasis of malignant tumors are associated with tumor angiogenesis, which is regulated by various vascular growth factors such as vascularendothelial growth factor (VEGF). Currently in the study of patients with gynecologic malignancies serum VEGF levels reported little. This study measured the serum levels of VEGF in patients with gynecologic malignancies and explored whether it could become a new tumor marker. MATERIALS AND METHODS: Preoperative sera from 50 cases of cervical cancer, 39 cases of endometrial cancer and 89 cases of ovarian cancer were detected by ELISA with Quantikine Horse VEGF kit manufactured by R & D SystemsIncminneapolisMNUSA, and 3 cases of 3, 9 months and relapse serum VEGF levels; the other with 80 healthy women serum VEGF levels as a control. Using SPSS9.0 statistical software package for statistical analysis. Describe the degree of variation using the 5th and 95th digit intervals. Results: The serum level of VEGF in 218 healthy women was 218.5ng / L (42.06-671.70ng / L). Preoperative blood VEGF levels in 50 cases of cervical cancer, 39 cases of endometrial cancer and 89 cases of ovarian cancer were 272.00ng / L (91.94-745.53ng / L), 383.50ng / L (105.67-776.50ng / L ) And 479.85ng / L (99.47-1326.88ng / L) respectively. The serum level of VEGF in patients with endometrial carcinoma and ovarian cancer was significantly higher than that in healthy women (P <0.0001). The serum levels of VEGF in preoperative cervical cancer patients were significantly higher than those in healthy women No significant difference (P> 0.05). Serum VEGF levels in 3 patients with ovarian cancer at 3, 6 and 9 months after operation were significantly lower than those before operation, of which 2 patients